leisure time -WSS

leisure time

author：focus 2025-10-01 23:00:38 - browse：943

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： The stability of $0 premiums in Medicare Advantage

WSS

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

CRISPR base editing slashes cholesterol levels in monkeys

Biden will tout long

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

6 solutions to address cancer drug shortages and others

WHO recommends second malaria vaccine

focus

leisure time

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The stability of $0 premiums in Medicare Advantage

The high cost of giving birth even with insurance

CRISPR base editing slashes cholesterol levels in monkeys

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lawsuit highlights wrinkle for disputes over surprise medical bills

How to save PrEP access — and even expand it

Congress extends some pandemic preparedness programs

Psychedelics group wrestles with new pharma identity

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

Wikipedia

Some top drug companies are starting to take action on climate

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

What will Novo Nordisk's VC do with its influx of cash?

IVG is promising — but it won’t replace IVF quite yet

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Wikipedia

focus

focus

hotspot